Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Gilead Sciences, INC

23 Nov 2000 07:40 AM <--

Return to Gilead Sciences, INC

GILD~(NASDAQ)
Gilead Sciences, Inc. provide
accelerated solutions for patients &
caretakers with a focus on developing
and marketing drugs to treat patients
with infectious diseases. For the 9
mos. ended 9/30/00, revenues rose
17% to $140.3M. Net loss fell 52% to
$27.5M. Revenues reflect royalties of
Tamiflu and increased sales and
royalties of AmBisome. Lower loss also
reflects the elimination of duplicate
S/G/A positions and the absence of
merger-related expenses.

~joarel